What Dicodin LP Treats: Main Uses and Benefits

Dicodin LP is applied across therapeutic domains where symptoms related to physical discomfort are significant and require stronger support. The active ingredient, dihydrocodeine, is primarily used to help manage moderate to severe pain, often applied when symptoms related to physical discomfort are not controlled by non-opioid options. Dicodin LP is considered relevant for easing long-term pain, managing acute post-operative pain, and addressing a persistent, non-productive cough.

The prolonged-release formulation is commonly used when symptoms that interfere with daily functioning are present, such as in cases involving chronic painful conditions like osteoarthritis. The consistent effect provides support that helps ease the overall symptom load and contributes to improved day-to-day comfort during symptomatic periods. It plays a role in managing symptomatic relief during phases of increased distress or discomfort.

The prolonged-release feature supports a continuous therapeutic effect that helps patients cope more steadily with symptom fluctuations.

Its secondary use contributes to improved comfort during symptomatic periods, and assists with managing symptoms that create noticeable functional strain, by easing the distress caused by a tiring cough.

Quick Fact: Relief for Persistent Discomfort
Primary Focus	Managing moderate to severe pain
Target Symptoms	Pain, persistent discomfort, non-productive cough
Formulation Benefit	Sustained and stable symptomatic relief

Population Eligibility and Contraindications

The eligibility profile for Dicodin LP (Dihydrocodeine Prolonged-Release) is strictly defined by regulatory warnings and exclusions concerning age, physiological status, and pre-existing conditions.

Classification	Eligibility Status	Specific Conditions/Restrictions
Absolute Contraindicated Populations	Must not use	All children under 12 years of age; Children under 18 years post-tonsillectomy/adenoidectomy; Patients with severe respiratory depression, severe bronchial asthma, or severe COPD; Patients with paralytic ileus or known gastrointestinal obstruction.
Conditional Use Populations	Use with Caution	Older adults (geriatric patients); Patients with renal or hepatic impairment; Individuals with hypothyroidism, raised intracranial pressure, or a history of seizure disorders.
Reproductive Eligibility	Not Recommended	Breastfeeding is not recommended due to risk of adverse infant effects. Pregnancy use is not recommended unless essential, due to risk of Neonatal Opioid Withdrawal Syndrome.
Concomitant Restriction	Must not use	Concurrent use of Monoamine Oxidase Inhibitors (MAOIs) or use within 14 days of MAOI therapy.

Eligibility is primarily restricted based on absolute prohibitions concerning age and physiological function, requiring cautious use for populations with compromised organ clearance or heightened sensitivity to central nervous system effects.

Dicodin LP (dihydrocodeine) may interact with several medicinal product categories, which can increase the risk of serious adverse effects. Interactions are primarily defined by the potential for additive effects on the central nervous system (CNS) and alterations to the drug's metabolism.

Clinically Significant Interactions

Interacting Product Category	Interaction Mechanism and Risk	Restriction Classification
Sedative Medicines (e.g., benzodiazepines, non-benzodiazepine hypnotics)	Additive CNS depressant effect, increasing the risk of profound sedation, respiratory depression, coma, and death.	Restrict Concomitant Use: Limit dose and duration to the minimum necessary.
Alcohol	Potentiation of CNS depressant effects, leading to impaired judgment and motor skills. May also affect the release of the prolonged-release formulation.	Contraindicated/Avoid Use: Patients should not consume alcohol or products containing alcohol.
Monoamine Oxidase Inhibitors (MAOIs)	Risk of serious, potentially fatal reactions.	Use with Caution/Warning: Caution is required if used within two weeks of stopping MAOI therapy.

Interactions Affecting Drug Metabolism

Dihydrocodeine is metabolized by specific liver enzymes. The concurrent use of medicines that either inhibit or induce these enzymes can alter the concentration of the drug in the body. Inhibitors (which may decrease metabolism) and inducers (which may increase metabolism) may affect the drug's efficacy or increase the risk of adverse effects. Patients should inform their healthcare provider about all current medications, including herbal supplements, to properly assess the risk of such pharmacokinetic interactions.

Mechanism of Action: Opioid Receptor Agonism

Dicodin LP is an opioid agonist that exerts its primary action through binding to the mu-opioid receptor (mu-OR), with lower affinity for the delta- (delta-OR) and kappa-opioid receptors (kappa-OR), within the central nervous system (CNS), including the brain and spinal cord.

Binding to these G-protein coupled receptors initiates a cascade of inhibitory intracellular signaling. Specifically, mu-OR activation inhibits adenylyl cyclase, leading to a decrease in intracellular cyclic adenosine monophosphate (cAMP). This G-protein mediated action also results in the hyperpolarization of neuronal membranes by increasing the conductance of potassium ions (K^+) and decreasing the presynaptic release of neurotransmitters (e.g., substance P, gamma-aminobutyric acid [GABA]) by reducing the influx of calcium ions (Ca^2+).

This mechanistic consequence results in the inhibition of ascending pain pathways, decreasing neuronal excitability, and altering the emotional response to nociception.

Dicodin LP is an oral medication with a prolonged-release (LP) formulation, meaning its use is structured around achieving sustained systemic delivery of the active ingredient, dihydrocodeine. The administration route is oral, and the tablet must be swallowed whole with a sufficient quantity of water, never crushed, chewed, or divided. Breaking the tablet would compromise the controlled-release mechanism, leading to the rapid release of the entire dose, which is contraindicated by the medication's design.

The dosing schedule is based on a fixed interval due to the formulation's design. The medicine is typically taken once or twice daily, spaced at appropriate intervals, such as every 12 hours, to ensure stable systemic exposure throughout the day. Standard adult regimens often begin with a dose of 60 mg of the prolonged-release tablet, and the total daily dose is subsequently managed within established therapeutic limits.

Regarding administration context, the medication can be taken with or without food. Standard protocols also include specific adjustments for certain populations. For instance, older adults or patients with known hepatic or renal impairment may require a lower initial dose or an adjustment to the dosing interval. Furthermore, the protocol for use dictates that the duration of treatment should be limited to the shortest time necessary, and gradual dose reduction (tapering) is a procedural step when concluding therapy after extended use.

Research Evidence / Overview of Studies for Dicodin LP

Evidence for Use in Moderate to Severe Pain

Research examining the use of the prolonged-release formulation for moderate to severe pain primarily involves Randomized Controlled Trials (RCTs). These studies were observed in adult patient populations, including those with chronic non-malignant pain and individuals with moderate cancer pain. The trials were applied in research contexts involving fluctuating or unstable symptoms.

Studies explored patient-reported pain intensity scores, the frequency of breakthrough pain, and the measurement of pain intensity variability over defined time intervals. Findings describe patterns observed in the studies when compared against other preparations, including short-acting formulations. One research analysis explored whether the long-acting formulation was associated with different outcomes related to pain stability compared to the immediate-release formulation; findings were mixed on this measure. Research provides insight into short-term changes, but further study is needed to fully understand long-term patterns.

Evidence for Use as an Antitussive (Cough)

The active ingredient was studied for use in research exploring non-productive cough, particularly in patient groups experiencing symptoms associated with primary or metastatic lung cancer. This research primarily involved short-term comparative clinical studies. Studies explored outcomes related to systemic or functional imbalance and monitored subjective metrics, such as patient- and investigator-graded cough severity scores. Comparative trials reported that measurements of antitussive effect were captured with the active substance when studied against other antitussive agents. The evidence contributes to the broader evidence landscape for traditional agents.

What Research Remains Uncertain About Dicodin LP

The long-term effects are not fully established for either application. For pain management, the duration of follow-up in key clinical studies was limited, typically lasting up to approximately nine weeks. Additionally, for both indications, follow-up durations were limited, meaning that long-term effects are not fully established. Overall, the quality of the evidence base varies across studies, and data for certain demographic subgroups remains insufficient, including older adult populations, children, and women who are pregnant. Research does not determine whether an individual will respond similarly.

Common questions about Dicodin LP (FAQ)

Q: What is the difference between Dicodin LP and standard Codeine tablets?

A: Dicodin LP contains dihydrocodeine, which is a substance related to codeine. The main difference lies in the dosage form: Dicodin LP is a prolonged-release (LP) tablet. This formulation is designed to release the medication slowly and consistently over a fixed time, typically 12 hours, to provide sustained pain relief, unlike standard immediate-release codeine.

---

Q: Can you feel 'high' or euphoric when taking Dicodin LP?

A: As an opioid analgesic, Dicodin LP has the potential to produce psychoactive effects. Official regulatory labels caution that the medicine carries a serious risk of addiction, abuse, and misuse. Information regarding addiction risks underscores the importance of using the medication strictly as prescribed by a healthcare provider.

---

Q: How quickly does Dicodin LP start working?

A: Dicodin LP is formulated as a prolonged-release tablet and is designed for controlled, sustained delivery, not rapid action. Studies show that peak blood levels of the active ingredient are typically reached within about two hours after swallowing the tablet.

---

Q: Are there any foods or drinks I should avoid while taking Dicodin LP?

A: Official warnings state that the use of alcohol is contraindicated because it can dangerously increase central nervous system effects, potentially leading to excessive sedation and breathing problems. Additionally, some regulatory information advises caution regarding certain food components, such as grapefruit juice, due to potential interactions with the drug's metabolism.

---

Q: What herbal supplements might interact with Dicodin LP?

A: The active substance in Dicodin LP is processed by specific liver enzymes. Official warnings advise caution with all concurrent medications, including herbal supplements. If a supplement is known to affect these liver enzymes, there is a potential for altered concentrations of Dicodin LP, which may affect the intended outcome or increase the risk of adverse effects.

---

Q: Does Dicodin LP affect my ability to drive?

A: Yes, regulatory documents indicate that Dicodin LP may cause common side effects such as drowsiness, dizziness, and somnolence. Patients are specifically warned that these effects are likely to impair their ability to operate vehicles or heavy machinery. The potential effects warrant caution, and operating vehicles or machinery should be avoided until an individual knows how the medicine affects them.

---

Q: What happens if I miss a dose of Dicodin LP?

A: Regulatory guidance addresses managing missed doses, which usually involves taking the dose if remembered soon after, or skipping it if it is nearly time for the next dose. Given the fixed-interval nature of the prolonged-release formulation, patients should follow the specific directions provided by their pharmacist or prescriber for their fixed schedule.

---

Q: Is it okay to take Dicodin LP only when the pain is severe?

A: Dicodin LP is a prolonged-release formulation specifically designed to be taken at fixed, regular intervals to maintain a stable and consistent level of medicine in the body. Taking it only 'as needed' would conflict with this controlled-release design, which is intended to provide continuous relief for persistent pain.

---

Q: How does the 'LP' mechanism work to release the medicine slowly?

A: The prolonged-release (LP) tablet is created using a special pharmaceutical design, often involving matrix or coating technology, to control the speed at which the active ingredient is dissolved and absorbed. This ensures the medicine is released gradually over many hours, which is why the tablets must be swallowed whole and never crushed or broken.

---

Q: Is there a specific way to stop taking Dicodin LP safely?

A: The drug should not be discontinued abruptly after prolonged use. To prevent potential withdrawal symptoms, regulatory guidance indicates that gradual reduction (tapering) is a required procedure when discontinuing the medication. This process must be managed by a healthcare professional.

---

Q: What is the risk of dependency or addiction with Dicodin LP?

A: As with all opioid medications, official labels emphasize that Dicodin LP carries a serious risk of developing drug addiction, dependence, and misuse. The risk exists even when the medication is used as prescribed. Official labels advise that the duration of treatment should be limited to the shortest time necessary to manage pain.

---

Q: Does Dicodin LP show up on a standard drug test?

A: The active substance in Dicodin LP is dihydrocodeine, which is eliminated from the body primarily through the urine. As a semi-synthetic opioid, the substance and its resulting metabolites can be detectable in standard drug screenings, depending on the specific test used and its threshold levels.

---

Q: Can Dicodin LP be taken on an empty stomach?

A: Official regulatory guidance states that Dicodin LP can generally be taken with or without food. The prolonged-release tablet is designed to be swallowed whole; crushing, chewing, or breaking the tablet would compromise its design.

---

Q: What should I do if the pain is not controlled by Dicodin LP?

A: If pain control is inadequate, regulatory documents advise that dosage regimens should be continually reevaluated by a healthcare professional. This assessment helps ensure the pain is managed effectively while minimizing the risk of adverse reactions.

---

Q: Can I store Dicodin LP in the bathroom medicine cabinet?

A: Official storage instructions require that the medicine be kept in a secure place, out of sight and reach of children and pets, and protected from moisture and high temperatures (typically not above 25 C). Due to humidity and temperature fluctuations in bathrooms, storage in a medicine cabinet may not meet the required conditions for protecting the medication's integrity.

---

Q: Are there specific warnings for people with lung or breathing issues?

A: Yes, the regulatory label includes a significant warning regarding respiratory safety. The drug is contraindicated (must not be used) in patients with pre-existing severe breathing issues, such as severe asthma or severe COPD, due to the inherent risk of life-threatening respiratory depression associated with opioid use.

---

Q: Why is Dicodin LP not recommended for children?

A: The medication is absolutely contraindicated (prohibited) in all children under 12 years of age and in children under 18 years following certain surgical procedures. This strict restriction is due to the severe and potentially fatal risk of respiratory depression associated with opioid metabolism in this population.

---

Q: Does Dicodin LP affect sleep quality?

A: Official product information highlights that the use of Dicodin LP is associated with the risk of Central Sleep Apnoea (CSA), a sleep-related breathing disorder. This condition can occur or worsen during opioid treatment, which may negatively impact the quality of sleep.

---

Q: How is Dicodin LP eliminated from the body?

A: The active ingredient is processed, or metabolized, primarily in the liver by specific enzymes. The drug and its resulting substances (metabolites) are then predominantly eliminated from the body through renal excretion, meaning they are passed out through the urine.

---

Q: What precautions should I take before surgery while on Dicodin LP?

A: Patients are generally advised to inform their healthcare provider and surgical team about the use of Dicodin LP before any procedure. This is important because the drug can interact with other central nervous system depressants, such as anesthetics, and caution is required, particularly in situations involving potential increases in intracranial pressure.

---

Q: Why might a doctor switch me from another painkiller to Dicodin LP?

A: The switch is often made when a patient requires treatment for moderate to severe pain that has not been adequately controlled by non-opioid options. Dicodin LP's prolonged-release formulation is typically chosen to provide a more consistent and stable level of pain relief throughout the day or night.

---

Q: Can I take Dicodin LP if I am pregnant or breastfeeding?

A: Official regulatory information states that use during pregnancy is generally not recommended because prolonged use near delivery can cause Neonatal Opioid Withdrawal Syndrome in the newborn. Breastfeeding is also not recommended due to the risk of the drug causing serious adverse effects, including severe central nervous system depression, in the nursing infant.

How to Store and Dispose of Dicodin LP (Dihydrocodeine Prolonged-Release Tablets)

Official regulatory documents provide specific instructions for the storage, handling, and disposal of this medication.

Storage and Handling

• Temperature: Do not store the tablets above 25 C.
• Security: This medication must be kept in a secure place, out of the sight and reach of children, teens, and pets.
• Container: Store Dicodin LP in its original container with the lid tightly closed to protect it from moisture and light.
• Integrity: The prolonged-release tablets must be swallowed whole. They must not be broken, chewed, or crushed, as this would compromise the tablet’s design.

Disposal

• Preferred Method: The safest way to dispose of unused or expired tablets is through an official drug take-back program or mail-back envelope.
• Household Disposal: If a take-back program is unavailable, mix the whole tablets with an unappealing substance, such as dirt or used coffee grounds, and place the mixture in a sealed bag before disposal in the household trash. Do not flush this medicine down the toilet or pour it down a sink.